A Phase II, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of TAK-385 10, 20, and 40 mg (p.o.) in the Treatment of Uterine Fibroids

Trial Profile

A Phase II, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of TAK-385 10, 20, and 40 mg (p.o.) in the Treatment of Uterine Fibroids

Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2017

At a glance

  • Drugs Relugolix (Primary)
  • Indications Uterine leiomyoma
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 09 May 2017 Results presented at the 65th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists.
    • 07 May 2017 Results published in a Myovant Sciences Media Release.
    • 07 May 2017 According to a Myovant Sciences media release, primary endpoint has been met. (Decrease in menstrual blood loss)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top